JP2018523485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523485A5 JP2018523485A5 JP2018509549A JP2018509549A JP2018523485A5 JP 2018523485 A5 JP2018523485 A5 JP 2018523485A5 JP 2018509549 A JP2018509549 A JP 2018509549A JP 2018509549 A JP2018509549 A JP 2018509549A JP 2018523485 A5 JP2018523485 A5 JP 2018523485A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- ccr
- acid sequence
- sequence encoding
- cytokine receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000003675 cytokine receptors Human genes 0.000 claims description 103
- 108010057085 cytokine receptors Proteins 0.000 claims description 103
- 150000007523 nucleic acids Chemical group 0.000 claims description 86
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 62
- 125000006850 spacer group Chemical group 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 31
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 102000042286 type I cytokine receptor family Human genes 0.000 claims description 10
- 108091052247 type I cytokine receptor family Proteins 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 4
- 101710120463 Prostate stem cell antigen Proteins 0.000 claims description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 2
- -1 CCL4 Proteins 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 2
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 2
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 2
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims description 2
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 230000004186 co-expression Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019113625A JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514875.2 | 2015-08-20 | ||
| GBGB1514875.2A GB201514875D0 (en) | 2015-08-20 | 2015-08-20 | Receptor |
| PCT/GB2016/052564 WO2017029512A1 (en) | 2015-08-20 | 2016-08-19 | Chimeric cytokine receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113625A Division JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523485A JP2018523485A (ja) | 2018-08-23 |
| JP2018523485A5 true JP2018523485A5 (enExample) | 2019-07-25 |
Family
ID=54292003
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509549A Withdrawn JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
| JP2019113625A Active JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
| JP2020199336A Active JP7603426B2 (ja) | 2015-08-20 | 2020-12-01 | キメラサイトカイン受容体 |
| JP2022178045A Withdrawn JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A Pending JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A Pending JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113625A Active JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
| JP2020199336A Active JP7603426B2 (ja) | 2015-08-20 | 2020-12-01 | キメラサイトカイン受容体 |
| JP2022178045A Withdrawn JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A Pending JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A Pending JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US10800854B2 (enExample) |
| EP (3) | EP4338756A3 (enExample) |
| JP (6) | JP2018523485A (enExample) |
| KR (2) | KR102669749B1 (enExample) |
| CN (2) | CN108350047A (enExample) |
| AU (1) | AU2016308618B2 (enExample) |
| BR (1) | BR112018003308A2 (enExample) |
| CA (2) | CA3091907C (enExample) |
| CL (2) | CL2018000415A1 (enExample) |
| GB (1) | GB201514875D0 (enExample) |
| HK (1) | HK1252161A1 (enExample) |
| IL (2) | IL270207B2 (enExample) |
| MX (2) | MX2018002042A (enExample) |
| RU (1) | RU2018109350A (enExample) |
| SG (1) | SG10201909759UA (enExample) |
| WO (1) | WO2017029512A1 (enExample) |
| ZA (1) | ZA201904156B (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| SG11201609118RA (en) | 2014-05-15 | 2016-11-29 | Univ Singapore | Modified natural killer cells and uses thereof |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2018094244A1 (en) | 2016-11-17 | 2018-05-24 | Bluebird Bio, Inc. | TGFβ SIGNAL CONVERTOR |
| CA3045667A1 (en) * | 2016-12-13 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| CN110636851B (zh) | 2017-03-27 | 2023-11-03 | 新加坡国立大学 | 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| AU2018329741B2 (en) * | 2017-09-08 | 2025-02-20 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| GB201714718D0 (en) | 2017-09-13 | 2017-10-25 | Autolus Ltd | Cell |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| GB201719557D0 (en) * | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| WO2019118895A1 (en) * | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Daric interleukin receptors |
| CA3089319A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| BR112020015884A2 (pt) | 2018-02-06 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple |
| US12240870B2 (en) | 2018-02-23 | 2025-03-04 | Purdue Research Foundation | Sequencing method for CAR T cell therapy |
| JP7526101B2 (ja) * | 2018-03-02 | 2024-07-31 | アロジーン セラピューティクス，インコーポレイテッド | 誘導性キメラサイトカイン受容体 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| SG11202009975TA (en) | 2018-04-12 | 2020-11-27 | Umoja Biopharma Inc | Viral vectors and packaging cell lines |
| SG11202007874XA (en) | 2018-04-27 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Rapamycin resistant cells |
| CA3103936A1 (en) * | 2018-06-18 | 2019-12-26 | Eureka Therapeutics, Inc. | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201812474D0 (en) | 2018-07-31 | 2018-09-12 | Autolus Ltd | Nucleic acid construct |
| EP3844186A4 (en) * | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| KR20210066865A (ko) | 2018-09-27 | 2021-06-07 | 오토러스 리미티드 | 키메라 항원 수용체 |
| WO2020097582A1 (en) * | 2018-11-08 | 2020-05-14 | WUGEN, Inc. | Compositions and methods for treatment of cancer |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| MY206523A (en) | 2019-03-01 | 2024-12-19 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| JP7602475B2 (ja) * | 2019-03-08 | 2024-12-18 | オートラス リミテッド | 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法 |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| GB201911187D0 (en) | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| JP2022548069A (ja) * | 2019-09-11 | 2022-11-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラ直交受容体タンパク質および使用方法 |
| KR102275668B1 (ko) | 2019-09-26 | 2021-07-12 | 충북대학교 산학협력단 | 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| WO2021072017A1 (en) * | 2019-10-10 | 2021-04-15 | Bryologyx Inc. | Method of induction of tumor associated antigens with bryostatin |
| IL295470A (en) | 2020-02-24 | 2022-10-01 | Allogene Therapeutics Inc | Bcma car-t cells with enhanced activities |
| EP4110801A1 (en) | 2020-02-25 | 2023-01-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| WO2021202793A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| EP4132962A1 (en) | 2020-04-09 | 2023-02-15 | Autolus Limited | Molecule |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| CN113201063B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途 |
| WO2022037562A1 (en) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Engineered immunoresponsive cells and uses thereof |
| CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
| CN113072648B (zh) * | 2021-06-04 | 2021-08-24 | 诺未科技（北京）有限公司 | 一种靶向afp的肝癌疫苗 |
| CN113416708A (zh) * | 2021-06-10 | 2021-09-21 | 深圳市先康达生命科学有限公司 | 一种表达细胞因子受体融合型嵌合抗原受体的免疫细胞及其应用 |
| US20230086030A1 (en) * | 2021-08-30 | 2023-03-23 | Industry-Academic Cooperation Foundation, Yonsei University | Lymphoma cell-specific drug delivery system for prevention or treatment of lymphoma and method for preparing same |
| WO2023044461A2 (en) * | 2021-09-17 | 2023-03-23 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| GB202115329D0 (en) | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| JP2025515134A (ja) * | 2022-05-04 | 2025-05-13 | アーリ インコーポレイテッド | 疾患細胞の位置を決定するおよび／または疾患細胞を処置するために表面発現可能な活性化可能エピトープを使用する方法 |
| EP4555072A1 (en) * | 2022-07-11 | 2025-05-21 | Sonoma Biotherapeutics, Inc. | Recombinant cytokine receptors and methods of use |
| JP2025529913A (ja) * | 2022-08-26 | 2025-09-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラサイトカイン受容体及び使用方法 |
| CN117402262A (zh) * | 2022-10-19 | 2024-01-16 | 上海君赛生物科技有限公司 | 基于lag3的嵌合免疫细胞辅助受体及其用途 |
| EP4630446A1 (en) * | 2022-12-06 | 2025-10-15 | Dynamic Cell Therapies, Inc. | Engineered switches for immune cell activity and methods of use thereof |
| US20240342214A1 (en) | 2023-01-23 | 2024-10-17 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| AU2024219048A1 (en) | 2023-02-07 | 2025-08-07 | Quell Therapeutics Limited | Culture method for treg cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| AU2024233625A1 (en) | 2023-03-03 | 2025-09-18 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
| CN120981564A (zh) | 2023-03-17 | 2025-11-18 | 圭尔医疗有限公司 | 调节性t细胞疗法 |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194630A1 (en) | 2023-03-20 | 2024-09-26 | Autolus Limited | A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma |
| WO2024238287A1 (en) * | 2023-05-12 | 2024-11-21 | Chimeris Uk Ltd. | Dual blocking and chimeric cytokine receptor |
| GB202309704D0 (en) | 2023-06-27 | 2023-08-09 | Autolus Ltd | Chimeric transmembrane protein |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| WO2025189046A2 (en) * | 2024-03-06 | 2025-09-12 | The Johns Hopkins University | Pantigen specific cytokine receptor stimulation of immune cell function |
| WO2025221843A1 (en) * | 2024-04-17 | 2025-10-23 | Baylor College Of Medicine | Methods and compositions for suppressing immune cell activation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029458A1 (en) | 1993-06-07 | 1994-12-22 | Amgen Inc. | Hybrid receptor molecules |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| ID28040A (id) * | 1998-05-19 | 2001-05-03 | Avidex Ltd | Reseptor sel t yang dapat larut |
| ATE432942T1 (de) * | 2001-03-09 | 2009-06-15 | Zymogenetics Inc | Löslicher heterodimerer cytokinrezeptor |
| DE60335536D1 (de) * | 2002-04-19 | 2011-02-10 | Bristol Myers Squibb Co | Verfahren zum nachweis oder zur modulierung der wechselwirkung eines cytokinrezeptors mit seinem ligand |
| JP2004113062A (ja) | 2002-09-25 | 2004-04-15 | Teruyuki Nagamune | キメラ受容体を有する動物細胞とその利用 |
| CN101027079B (zh) * | 2004-10-12 | 2011-08-17 | 美国蛋白质公司 | 嵌合蛋白 |
| WO2007115230A2 (en) | 2006-03-30 | 2007-10-11 | University Of Medicine And Dentistry Of New Jersey | A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| EP2173377B1 (en) * | 2007-06-26 | 2017-11-29 | University of Miami | Antibody-endostatin fusion protein and its variants |
| WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| CA2832569A1 (en) | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| US9447194B2 (en) | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
| RU2522004C2 (ru) | 2012-04-10 | 2014-07-10 | Владимир Константинович Боженко | Одноцепочечное антитело к раково-эмбриональному антигену, химерный мономолекулярный т-клеточный рецептор, вектор и клетка-хозяин для обеспечения экспрессии такого рецептора и способ диагностики или лечения. |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| MA41538A (fr) | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| KR20210066865A (ko) | 2018-09-27 | 2021-06-07 | 오토러스 리미티드 | 키메라 항원 수용체 |
-
2015
- 2015-08-20 GB GBGB1514875.2A patent/GB201514875D0/en not_active Ceased
-
2016
- 2016-08-19 IL IL270207A patent/IL270207B2/en unknown
- 2016-08-19 WO PCT/GB2016/052564 patent/WO2017029512A1/en not_active Ceased
- 2016-08-19 KR KR1020187007751A patent/KR102669749B1/ko active Active
- 2016-08-19 EP EP23216609.0A patent/EP4338756A3/en active Pending
- 2016-08-19 RU RU2018109350A patent/RU2018109350A/ru unknown
- 2016-08-19 AU AU2016308618A patent/AU2016308618B2/en active Active
- 2016-08-19 US US15/753,486 patent/US10800854B2/en active Active
- 2016-08-19 CN CN201680046834.3A patent/CN108350047A/zh active Pending
- 2016-08-19 SG SG10201909759U patent/SG10201909759UA/en unknown
- 2016-08-19 BR BR112018003308-1A patent/BR112018003308A2/pt not_active Application Discontinuation
- 2016-08-19 EP EP18189793.5A patent/EP3438123A1/en active Pending
- 2016-08-19 CA CA3091907A patent/CA3091907C/en active Active
- 2016-08-19 HK HK18111554.5A patent/HK1252161A1/zh unknown
- 2016-08-19 MX MX2018002042A patent/MX2018002042A/es unknown
- 2016-08-19 KR KR1020247017118A patent/KR20240093884A/ko active Pending
- 2016-08-19 EP EP16756758.5A patent/EP3337814A1/en active Pending
- 2016-08-19 CN CN201911010436.8A patent/CN110724200B/zh active Active
- 2016-08-19 CA CA2995785A patent/CA2995785A1/en not_active Abandoned
- 2016-08-19 JP JP2018509549A patent/JP2018523485A/ja not_active Withdrawn
-
2018
- 2018-01-30 IL IL257234A patent/IL257234A/en unknown
- 2018-02-15 CL CL2018000415A patent/CL2018000415A1/es unknown
- 2018-02-16 MX MX2019013204A patent/MX2019013204A/es unknown
- 2018-08-27 US US16/113,224 patent/US10800855B2/en active Active
-
2019
- 2019-04-23 CL CL2019001107A patent/CL2019001107A1/es unknown
- 2019-06-19 JP JP2019113625A patent/JP6979423B2/ja active Active
- 2019-06-26 ZA ZA2019/04156A patent/ZA201904156B/en unknown
-
2020
- 2020-08-20 US US16/999,012 patent/US11479614B2/en active Active
- 2020-08-20 US US16/998,756 patent/US11479613B2/en active Active
- 2020-12-01 JP JP2020199336A patent/JP7603426B2/ja active Active
-
2022
- 2022-07-26 US US17/815,110 patent/US12234295B2/en active Active
- 2022-11-07 JP JP2022178045A patent/JP2022190153A/ja not_active Withdrawn
-
2025
- 2025-01-21 US US19/033,252 patent/US20250333538A1/en active Pending
- 2025-03-21 JP JP2025047075A patent/JP2025089404A/ja active Pending
- 2025-03-21 JP JP2025047074A patent/JP2025089403A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523485A5 (enExample) | ||
| JP7660382B2 (ja) | 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用 | |
| RU2018109350A (ru) | Химерный цитокиновый рецептор | |
| JP6867347B2 (ja) | 免疫療法のためのエンゲージャー細胞 | |
| TWI890655B (zh) | 改良之抗原結合受體 | |
| ES2949364T3 (es) | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA | |
| JP2019150066A5 (enExample) | ||
| Krebs et al. | T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1 | |
| US20200093861A1 (en) | Antigen binding receptor formats | |
| JP2021035395A5 (enExample) | ||
| CN112088008A (zh) | 修饰细胞的扩增及其用途 | |
| JP2025063189A (ja) | 遺伝子操作された細胞の組成物および関連組成物を産生するための方法 | |
| KR20160062762A (ko) | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 | |
| KR102316091B1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| JP2025512797A (ja) | 改善されたキメラ受容体 | |
| CA3225682A1 (en) | Anti-egfrviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition comprising said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptid | |
| CA3174779A1 (en) | Cd28h domain-containing chimeric antigen receptors and methods of use | |
| Krebs et al. | T cells redirected to IL13Rα2 with IL13 mutein-CARs have antiglioma activity but also recognize IL13Rα1 | |
| WO2025134168A1 (en) | Genetically modified immune cells for the treatment of tumors and autoimmune diseases | |
| EP4372089A1 (en) | Chimeric antigen receptor, cell capable of expressing said receptor, pharmaceutical composition containing said cell, method for producing said cell, and polynucleotide or vector which contains nucleotide sequence encoding said chimeric antigen receptor | |
| JP2025540660A (ja) | Ｃｔｌａ－４変異体及びキメラ抗原受容体を用いた二重遺伝子導入免疫細胞及びその用途 | |
| Garg | Development of fully-human macrophage-modulatory antibodies for cancer immunotherapy | |
| 한제롬 | Application of anti-C4d antibody as chimeric antigen receptor regulatory T cell (CAR-Treg) and bispecific T cell engager (BiTE) | |
| CN120548323A (zh) | 利用ctla-4变体及嵌合抗原受体的双基因转导免疫细胞及其用途 | |
| CA3226947A1 (en) | Engineered tcr complex and methods of using same |